NBY

Novabay Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↓ 4/10
  • Value↑ 6/10
Novabay Pharmaceuticals sales and earnings growth
NBY Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 70.03%
  • FCF Y/Y↓ -12.44%
Novabay Pharmaceuticals gross and profit margin trends
NBY Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -635.32%
Novabay Pharmaceuticals recent dividend growth
NBY Dividends
  • Dividend yield 327.87%
  • Growth 3Y↓ 0.00%
  • Payout ratio↑ -105%
Novabay Pharmaceuticals net debt vs free cash flow
NBY Risk
Great
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Novabay Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗